Funding the next wave of biopharma innovation
Our firm
We operate at the intersection of science, medicine and investing
We are the world’s largest buyer of biopharmaceutical royalties and a leading funder of innovation in life sciences.
Learn morePartners
Partner with us
We are the leading partner funding innovation in life sciences with more than 60% global market share. Our unique capabilities to provide tailored funding solutions and customize win-win partnerships have positioned us as the partner of choice in the biopharma ecosystem.
Investors
Inaugural Investor Day
Royalty Pharma Investor Day highlights stronger growth outlook and the power of its unique business model to do drive value for all stakeholders.
Stock information
RPRX
Latest quarterly earnings
Q3 2024
News
Latest developments
Royalty Pharma Reports Third Quarter 2024 Results
Royalty Pharma And Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement For Niktimvo
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
Responsibility
Creating value for stakeholders
We create value for our stakeholders by funding innovation across the life sciences ecosystem. Our policies and practices are designed to minimize our sustainability-related risk and uphold our commitments to our stakeholders and partners.
Accelerating Bio-Innovation
At the leading edge of life sciences
Held in partnership with the University of Cambridge and the Massachusetts Institute of Technology since 2019, the Accelerating Bio-Innovation Conference is an interdisciplinary summit that brings to light the triumphs and hurdles in drug discovery and development. The event brings together thought leaders from the bio-innovation sphere to engage in crucial debates and discussions confronting pioneers in the world of new biopharmaceuticals, bridging the realms of science, investing and innovative therapeutics.
Find out more